Seegene Inc

More advanced solution for COVID-19 and variants

Seegene is playing a critical role in developing effective testing solution to mitigate the spread of rapidly mutating COVID-19 and variants.

Full Screening and Identification
for SARS-CoV-2 and Variants

Full screening for SARS-CoV-2 and Variants

Full screening for SARS-CoV-2 and variants
including the five notable mutations in S gene

Identification of SARS-CoV-2 Variants

Identification of major SARS-CoV-2 variants of
concern and highly conserved region in RdRP gene

Identification of SARS-CoV-2 Variants

Identification of major SARS-CoV-2
variants of concern

Notable Variants and Key Mutations

Seegene utilizes bioinformatics (SG-Insilico™) to monitor newly emerging SARS-CoV-2 sequence information on a regular basis and design optimized diagnostic assay.

Pre-ECCMID 2021
Day on COVID-19 (Part One)

This session is now available online.

An Innovative Approach to Infection Control

SARS-CoV-2 and Variants Full-Screening Solution : Seegene Master Assay
Guy Wilhem Lee (Republic of Korea)
Seegene’s One Platform for Mass Testing, Coinfections,
and Variants in COVID-19
Nackmoon Sung (Republic of Korea)

Industry Flash Session

July 11 (Sun), 13:15-14:15 CEST

The New Era of COVID-19
Chair: Carsten Tiemann (Germany)

Decreased SARS-CoV-2 Viral Load After Inoculation with the BNT162b2 Vaccine
Idan Yelin (Israel)
SARS-CoV-2 & Variants
Federico Garcia (Spain)

If you are a registrant of ECCMID 2021 Virtual Meeting, you can join Seegene symposium on ECCMID 2021 virtual congress site.

ECCMID Virtual Congress Site

Multiplex Real-time PCR assay portfolio
for COVID-19 and Variants


Allplex™ 2019-nCoV Assay

  • - N gene
  • - RdRP gene
  • - E gene
  • - Internal control (IC)

Allplex™ SARS-CoV-2 Assay

  • - N gene
  • - S gene
  • - RdRP gene
  • - E gene
  • - Internal control (IC)

Allplex™ SARS-CoV-2
/FluA/FluB/RSV Assay

  • - N gene
  • - S gene
  • - RdRP gene
  • - Influenza A
  • - Influenza B
  • - RSV A/B
  • - Endogenous internal control (IC)
  • - Exogenous internal control (IC)

Allplex™ SARS-CoV-2
Master Assay

  • - E gene
  • - N gene
  • - RdRP/S gene
  • - HV 69/70 deletion, N501Y, E484K, Y144 deletion and P681H in S gene
  • - Endogenous internal control (IC)

Allplex™ SARS-CoV-2
Variants I Assay

  • - RdRP gene
  • - E484K in S gene
  • - N501Y in S gene
  • - HV69/70 deletion in S gene
  • - Endogenous internal control (IC)

Allplex™ SARS-CoV-2
Variants II Assay

  • - L425R in S gene
  • - W152C in S gene
  • - K417N in S gene
  • - K417T in S gene
  • - Endogenous internal control (IC)

Overview of product selection criteria

Expanded selectivity of syndromic test

Allplex™ SARS-CoV-2 Master Assay can be used alone or expanded to syndromic test with respiratory essential panel for common respiratory infections, including influenza A and B, metapneumovirus, parainfluenza virus 1/2/3/4, adenovirus, rhinovirus A/B/C and respiratory syncytial virus A/B, to provide more insights for diagnosis of symptomatic patients especially with the emerging SARS-CoV-2 variants.

Primary screening for COVID-19, Flu and RSV

Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is designed to detect and differentiate between SARS-CoV-2, influenza A, influenza B and RSV
for primary screening during the upcoming flu season.

More reliable results using dual internal controls

- The endogenous and exogenous internal controls are designed to verify the entire process from sample collection to nucleic acid extraction and PCR steps

- The endogenous internal control enables validating correct sampling for self-collected specimens

Increased accuracy by minimizing risks

Multiplex real-time PCR with high sensitivity and specificity by utilization of Seegene’s proprietary technologies

Detecting N, S, RdRP and/or E target genes of SARS-CoV-2 to minimize the risk of genetic variations and allow high accuracy 

No cross-reactivity confirmed with respiratory pathogens including SARS, MERS and SARS-related viruses

Premium Platform for Post Analysis and Statistics

SG STATS, Seegene’s premium platform of advanced statistical analysis provides fast and accurate data analysis and management of PCR results.
To combat SARS-CoV-2 and variants, SG STATS helps monitor real-time variant trend and discover insights for its forecast. The web-based platform also provides in-depth analysis by variable factors such as vaccination, gender etc.

Variant trend monitoring

Real-time variant trend monitoring for targeted patient group by geography, age etc.

Detection of unknown mutation

Data visualization
by combination of mutations

In-depth variant analysis

Ct-value available by vaccination, symptom and other researcher’s preference

Powerful automation platform

Seegene’s automated molecular diagnostic platform allows a unique streamlined workflow with quick and simple steps for detection of COVID-19.  


Automated Extraction & PCR Setup
> View more


Detection by Real-time PCR
>View more

Seegene Viewer

Automated Interpretation
>View more


Web-based Statistical Data Analysis

Kick your Real-time PCR up a notch!

With Seegene’s core technologies and proprietary know-hows, enhance your MDx products with incomparable performance and usability.

Oligo Design

Oligo design technology for high multiplex PCR: SG-Insilico™

Enables rapid designing of high multiplex oligos using Seegene-developed algorithms and confidential variables.


Highly specific amplification technology for high multiplex PCR: DPO™

Allows the implementation of high multiplex diagnostics with unparalleled specificity using Seegene’s unique primer structure.

Target Detection

High multiplex target detection technology: TOCE™

Achieves accurate target signals by independently controlling multiple target signals for primer and probe annealing temperatures.


High multiplex target detection & quantification technology: MuDT™

Broadens capacity for high multiplex target detection & quantification by enabling analysis of multiple Ct values in a single detection channel.


High multiplex signal processing technology: DSP™

Enables accurate reporting of target’s positive or negative results through Seegene’s proprietary signal processing algorithms.


[1] Allplex™ 2019-nCoV Assay has not been FDA cleared or approved. This test has been authorized by FDA under an emergency use authorization for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner.

[2] Allplex™ SARS-CoV-2/Flu A/Flu B/RSV Assay, SARS-CoV-2 Assay and RV Essential Assay are intended for in vitro diagnostic use in Europe and not available in all countries.